Korean J Gastroenterol.  2025 Jan;85(1):93-95. 10.4166/kjg.2024.155.

Clinical Benefits and Adverse Effects of Vonoprazan in Long-Term Maintenance Therapy

• Noh JH

• KMID: 2565022
• DOI: http://doi.org/10.4166/kjg.2024.155

Reference

1. Uemura N, Kinoshita Y, Haruma K, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol. 2024; Aug. 27. doi: 10.1016/j.cgh.2024.08.004. DOI: 10.1016/j.cgh.2024.08.004. PMID: 39209187.

2. Freedberg DE, Kim LS, Yang YX. 2017; The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 152:706–715. DOI: 10.1053/j.gastro.2017.01.031. PMID: 28257716.

3. Shah NH, LePendu P, Bauer-Mehren A, et al. 2015; Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 10:e0124653. DOI: 10.1371/journal.pone.0124653. PMID: 26061035. PMCID: PMC4462578.

4. Zirk-Sadowski J, Masoli JA, Delgado J, et al. 2018; Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 66:1332–1338. DOI: 10.1111/jgs.15385. PMID: 29676433. PMCID: PMC6099478.

5. Moayyedi P, Eikelboom JW, Bosch J, et al. 2019; Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 157:682–691.e2.

6. Vaezi MF, Yang YX, Howden CW. 2017; Complications of proton pump inhibitor therapy. Gastroenterology. 153:35–48. DOI: 10.1053/j.gastro.2017.04.047. PMID: 28528705.

7. Laine L, DeVault K, Katz P, et al. 2023; Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: A randomized trial. Gastroenterology. 164:61–71. DOI: 10.1053/j.gastro.2022.09.041. PMID: 36228734.

8. Ashida K, Iwakiri K, Hiramatsu N, et al. 2018; Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 24:1550–1561. DOI: 10.3748/wjg.v24.i14.1550. PMID: 29662293. PMCID: PMC5897859.

9. Ashida K, Sakurai Y, Hori T, et al. 2016; Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 43:240–251. DOI: 10.1111/apt.13461. PMID: 26559637. PMCID: PMC4738414.

10. Tatsuguchi A, Hoshino S, Kawami N, et al. 2020; Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa. Pathol Res Pract. 216:153113. DOI: 10.1016/j.prp.2020.153113. PMID: 32853950.

11. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. 2015; Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 42:649–663. DOI: 10.1111/apt.13324. PMID: 26177572.

12. McCarthy DM. 2020; Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids-What is the relationship? Int J Mol Sci. 21:662. DOI: 10.3390/ijms21020662. PMID: 31963924. PMCID: PMC7014182.